Researchers at UC, San Diego verified a suspect gene mutation in blood-forming stem cells was by itself necessary and sufficient to cause a class of severe blood diseases called myeloproliferative disorders. They then worked with researchers from other academic institutions and the San Diego pharmaceutical company TargeGen to conduct animal tests of a compound TargeGen … Continue reading CIRM’s first clinical Trial Begins for a Therapy Enabled By CIRM Funding